Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue.
Sanofi India share price rises up to 6% post Q4 results, Dividend announcements
Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...
pharmaphorum23d
GSK, Sanofi eye Q4 approval as COVID jab starts phase 3
GlaxoSmithKline's COVID-19 drive has advanced on two fronts, with the start of phase 3 trials of its Sanofi-partnered vaccine candidate as well as an FDA emergency approval for antibody sotrovimab ...
Research Analysts Set Expectations for Sanofi Q2 Earnings
Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th. Zacks Research analyst K. Shah now forecasts that the company will post ...
Mint20d
Sanofi Consumer Healthcare India Q4 Results 2025: Profit Falls by 34.66% YoY
Sanofi Consumer Healthcare India Q4 Results 2025:Sanofi Consumer Healthcare India declared their Q4 results on 20 Feb, 2025. The topline decreased by 20.53% year-over-year (YoY), with profit ...
Seeking Alpha28d
Sanofi and J&J discontinue late stage trial of their experimental E.coli vaccine
Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 IFRS results. It will further negatively impact the full-year IFRS EPS ...
ETF Daily News5d
Zacks Research Has Bearish Estimate for Sanofi Q2 Earnings
Zacks Research also issued estimates for Sanofi’s Q4 2025 earnings at $0.80 EPS, FY2025 earnings at $4.14 EPS, Q1 2026 earnings at $1.00 EPS, Q3 2026 earnings at $1.36 EPS, Q4 2026 earnings at $ ...
Sanofi India shares rise 4% on strong topline and operational show, net profit sharply lower
Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships.
Benzinga.com28d
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
coli disease. Sanofi recorded a $250M impairment charge, lowering Q4 2024 IFRS EPS by €0.15 to €4.44, while business net income and EPS remain unchanged. Our government trade tracker caught ...
A Boon For Investors! Pharma Giant Recommends Massive Dividend of Rs 117; A Solid Move For Shareholder Value?
With a market valuation of Rs 11,574.76 Cr, Sanofi Indias shares ended Fridays trading session on the BSE 0.58% higher at Rs ...
AOL28d
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
As a result of the discontinuation, Sanofi has recorded an impairment charge before tax of $250 million in the Q4 2024 IFRS results. This adjustment negatively impacts the full-year IFRS EPS ...